title: Is disease recurrence still relevant to graft survival?
authors.affiliation: Baylor University Medical Center, Dallas, TX.
authors.forename: James F
authors.initials: JF
authors.lastname: Trotter
mesh_terms: D015551:Autoimmunity; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D002758:Cholangiography; D002761:Cholangitis / Q000628:therapy; D005234:Fatty Liver / Q000628:therapy; D006085:Graft Survival; D006509:Hepatitis B / Q000150:complications / Q000628:therapy; D006526:Hepatitis C / Q000150:complications / Q000628:therapy; D019693:Hepatitis, Autoimmune / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D007166:Immunosuppressive Agents; D017093:Liver Failure / Q000503:physiopathology* / Q000628:therapy*; D008113:Liver Neoplasms / Q000628:therapy; D016031:Liver Transplantation; D065626:Non-alcoholic Fatty Liver Disease; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents